Drug

Pharmacologic Class

Indication

More Information

Dermatological Disorders
Vtama® (tapinarof cream) Aryl hydrocarbon receptor agonist Topical treatment of plaque psoriasis. Steroid-Free Vtama Cream Approved for Plaque Psoriasis
Endocrine Disorders
Mounjaro (tirzepatide) Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist An adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro Drug Monograph
Gastrohepatic Disorders
Dupixent® (dupilumab) Interleukin-4 receptor alpha antagonist Treatment of eosinophilic esophagitis in patients 12 years of age and older weighing at least 40kg. Dupixent Drug Monograph
Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) Small molecule potassium-competitive acid blocker Treatment of Helicobacter pylori (H. pylori) infection in adults. Voquezna Triple, Dual Pak Approved for H. Pylori Infection Treatment
Infectious Disease
Olumiant® (baricitinib) Janus kinase (JAK) inhibitor Treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. Olumiant Approved for COVID-19 Treatment in Hospitalized Adults
Oncology
Enhertu® (fam-trastuzumab deruxtecan-nxki)  

HER2-directed antibody + topoisomerase inhibitor conjugate

Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. Enhertu Drug Monograph
Kymriah (tisagenlecleucel) CD19-directed genetically modified autologous T cell immunotherapy Treatment of adults with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy. Kymriah Drug Monograph
Rare Diseases
Cuvrior™ (trientine tetrahydrochloride) Copper chelator Treatment of adults with stable Wilson disease who are de-coppered and tolerant to penicillamine. Cuvrior Gets FDA Approval for Wilson Disease